pharmaphorum

FDA clears trial of 'vectorised' ALS antibody from VectorY

Dutch start-up VectorY Therapeutics has been given the green light by the FDA for a phase 1/2 trial of a drug against a target implicated in up to 97% of amyotrophic lateral sclerosis (ALS) cases. VTx ...
PharmiWeb

ProteoNic 2G UNic® Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies

ProteoNic BV, a leading provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic® technology has been licensed by Ginkgo ...
The Caledonian-Record

uBriGene Launches LVV Turbo(TM) - Its Next-Generation GMP Lentiviral Vector Manufacturing Platform - and announces a Strategic Partnership with Syenex for int…

GERMANTOWN, MD AND CHICAGO, IL / ACCESS Newswire / December 16, 2025 / uBriGene Biosciences, a leading global lentivirus CDMO ...
Business Wire

VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology ...

AMSTERDAM & BOSTON--(BUSINESS WIRE)--VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) ...
Le Lézard

Gene Therapies for Cardiomyopathies Market Poised for Rapid Expansion During the Forecast Period (2025-2034) with Advancements in AAV and CRISPR Platforms | DelveInsight

DelveInsight's Gene Therapies for Cardiomyopathies Market Insights report includes a comprehensive understanding of current treatment practices, emerging gene therapies for cardiomyopathies, market ...
MedPage Today on MSN

Gene Therapy-Induced CAR T Cells for Myeloma Could Alter Treatment Landscape

ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable ...
The American Journal of Managed Care

In Vivo CAR T Takes Center Stage, With Results Shared for 4 MRD-Negative Patients

Kelonia Therapeutics' KLN-1010 has shown promising early results in a phase 1 trial for relapsed or refractory multiple ...
Labiotech.eu

Keep an eye on these 15 biotech companies in 2026

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...
Le Lézard

Lake City Bank Partners with Spiral to Support Financial Wellness and Community Impact Through Everyday Banking

Spiral, the award-winning platform redefining personalized banking, today announced a partnership with Lake City Bank, a leading Indiana-based bank. The partnership provides Lake City Bank with a ...
FierceBiotech

J&J's $5B Alzheimer's hope fades as anti-tau antibody posdinemab flops in phase 2

Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. A scheduled data review found the anti-tau antibody posdinemab failed to ...

Fondazione Telethon Announces FDA approval of Waskyra(TM) (etuvetidigene autotemcel), a Gene Therapy for the Treatment of Wiskott-Aldrich Syndrome

ROME, Italy, Dec. 10, 2025 /PRNewswire/ -- Fondazione Telethon announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Waskyra, an ex ...
BioWorld

US lawmakers demand that Kennedy be held accountable

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are growing. Claiming that Kennedy has turned ...